The LIFESAVER project is revolutionizing drug safety for expectant mothers and their unborn children, addressing a critical gap in pharmaceutical development.
The LIFESAVER project is revolutionizing drug safety for expectant mothers and their unborn children, addressing a critical gap in pharmaceutical development.
At LIFESAVER, we’re proud to be part of the European Green Deal’s ambitious vision: a Europe free from pollution by 2050. This vision, outlined in the European Commission’s Chemicals Strategy for Sustainability, calls for bold action to protect humans and the environment from hazardous chemicals.
In the complex world of maternal and fetal healthcare, early and accurate detection of health issues can make a vital difference. Traditionally, diagnostic technologies have struggled to keep pace with the sensitivity and speed required in this field, often limiting healthcare providers and patients alike. Enter LIFESAVER—a project dedicated to bridging this gap through advanced biosensing technology. With AptaShield, LIFESAVER is changing how we monitor maternal and fetal health, enabling timely interventions and safer pregnancies.
In the complex world of maternal and fetal healthcare, early and accurate detection of health issues can make a vital difference. Traditionally, diagnostic technologies have struggled to keep pace with the sensitivity and speed required in this field, often limiting healthcare providers and patients alike. Enter LIFESAVER—a project dedicated to bridging this gap through advanced biosensing technology. With AptaShield, LIFESAVER is changing how we monitor maternal and fetal health, enabling timely interventions and safer pregnancies.
By focusing on the intricate processes of placental development, this research lays the groundwork for advanced strategies to ensure maternal and fetal health
In the pursuit of safer pharmaceutical interventions during pregnancy, it is critical to have reliable and precise preclinical data. The LIFESAVER project, dedicated to advancing risk assessment for drugs and chemicals affecting pregnant women, heavily relies on innovative methodologies to ensure drug safety and efficacy.
In “Pioneering Biomarker-Based Analytics in LIFESAVER: Revolutionising Maternal Health Safety,” we explore the groundbreaking approach of the LIFESAVER Project, which stands at the vanguard of enhancing maternal health safety through biomarker-based analytics. By utilizing sophisticated biomarkers, this initiative is setting new benchmarks in the early detection of potential risks during pregnancy, ensuring safer protocols for drug and environmental chemical exposure. This blog post delves into the transformative potential of biomarkers in revolutionizing disease diagnosis and therapeutic interventions, highlighting their role in advancing personalized and timely healthcare. Through the integration of cutting-edge biosensing technology and a focus on interdisciplinary collaboration, the LIFESAVER Project promises a brighter future for maternal and fetal health, emphasizing precision, safety, and the importance of personalized care. Join us in this journey towards a new era of healthcare innovation, where maternal well-being and fetal health are prioritized with unparalleled rigor and dedication.
With the rising prevalence of drug use during pregnancy, there are growing concerns regarding the potential dangers these substances may pose to developing embryos and fetuses,
especially for drugs that do not have adequate safety data available. Substances with unverified or dubious safety profiles could introduce significant risks, potentially causing harm to the unborn child
Digital Placenta On-a-chip: Malta is partnering in EU-funded research to help pregnant women minimise risks to the foetus from potentially harmful chemical and medicinal products.
The Malta Innovation Hub at the Malta Life Sciences Park is this week hosting the other partners of the LIFESAVER Horizon funded project.
